Budesonide Formoterol Inhaler for Asthma and COPD

Budesonide formoterol is a combination inhaler containing two medications that work in complementary ways: budesonide, an inhaled corticosteroid that reduces airway inflammation, and formoterol, a long-acting bronchodilator that relaxes the muscles around the airways. Sold under brand names like Symbicort, it is prescribed for both asthma and chronic obstructive pulmonary disease (COPD) and has become central to modern treatment guidelines, partly because of an unusual property: formoterol works fast enough that the combination can serve as both a daily controller and an as-needed rescue inhaler in a single device.

How the Two Drugs Work Together

Budesonide acts on multiple immune and structural cells in the airways, dampening the chronic inflammation that drives asthma and COPD flare-ups.¹ Formoterol, meanwhile, is a highly selective beta-2 agonist that combines rapid onset of action with a duration exceeding twelve hours.² That rapid onset is what sets formoterol apart from salmeterol, the other commonly used long-acting bronchodilator. Formoterol’s moderate lipophilicity lets it reach bronchial smooth muscle quickly for fast relief, while a portion of the drug deposits within the muscle cells and leaches out gradually, sustaining the effect for hours.³

Pairing a corticosteroid with a long-acting beta-2 agonist is not just a matter of stacking two separate benefits. Laboratory work shows these drug classes interact at the molecular level. At low concentrations, combining a corticosteroid with a beta-2 agonist synchronizes the activation of certain transcription factors in airway smooth muscle, producing a stronger anti-proliferative effect than either drug alone. This has led researchers to suggest that the corticosteroid dose can be reduced when the two drugs are given together, which could minimize side effects.⁴ Broader evidence confirms that corticosteroid–beta-2 agonist combinations have complementary and sometimes synergistic effects on inflammatory pathways, mediator release, and the survival of inflammatory cells in the airways.⁵ One specific example involves lung fibroblasts, where the budesonide-formoterol combination synergistically reduced a tissue inhibitor involved in airway remodeling.⁶

The Single-Inhaler Strategy for Asthma

For decades, asthma care relied on a simple two-inhaler model: a daily controller (usually an inhaled steroid) plus a separate rescue inhaler (a short-acting bronchodilator like albuterol or salbutamol) for sudden symptoms. Budesonide formoterol disrupted that model. Because formoterol opens the airways within minutes, patients can take the same combination inhaler both as a scheduled morning and evening dose and as a rescue puff when symptoms break through. Each rescue puff delivers an extra dose of anti-inflammatory budesonide exactly when the airways are flaring, which acts as a built-in escalation of treatment.⁷

Current global guidelines have embraced this approach. The 2024 GINA (Global Initiative for Asthma) strategy now advises that all adults and adolescents with asthma receive an inhaled corticosteroid-containing medication, rather than being treated with a short-acting bronchodilator alone. The preferred treatment track uses as-needed low-dose budesonide-formoterol as the reliever at every step of asthma severity.⁸ This was a significant shift, because it means that even patients with the mildest asthma are now recommended an anti-inflammatory reliever rather than a plain bronchodilator.

Evidence in Mild Asthma

The guideline change was driven by several large trials. In one, patients with mild asthma who used budesonide-formoterol only as needed had roughly half the exacerbation rate of those using albuterol alone, and their rate of severe exacerbations was about 60% lower.⁹ Strikingly, the as-needed budesonide-formoterol group also had fewer severe exacerbations than a group taking daily budesonide maintenance plus an as-needed short-acting bronchodilator, despite using far less total steroid. A separate large trial found that as-needed budesonide-formoterol was statistically noninferior to daily budesonide for severe exacerbation rates.¹⁰ A year-long trial from New Zealand supported these findings, concluding that budesonide-formoterol reliever therapy was a valid alternative to daily low-dose inhaled corticosteroid for patients with mild asthma.¹¹

Adolescents show the same pattern. In the SYGMA 1 trial, teenagers using as-needed budesonide-formoterol had a 77% lower rate of severe exacerbations compared with those using a short-acting bronchodilator alone.¹² And in younger children aged five to fifteen, a 2025 trial found that budesonide-formoterol reliever monotherapy cut asthma attacks by about 45% compared with salbutamol, with a similar safety profile.¹³

Moderate and Severe Asthma

In patients whose asthma is harder to control, the single-inhaler approach carries even more weight. A meta-analysis of patients with poorly controlled asthma found that switching to budesonide-formoterol as both maintenance and reliever reduced the risk of a first severe exacerbation by about 30% compared with staying on the same fixed-dose regimen or stepping up to a higher dose of a fixed combination plus a separate rescue inhaler.¹⁴ A randomized trial found that participants using the combined maintenance-and-reliever approach had roughly half the rate of severe exacerbations compared with the control group.¹⁵

A key advantage is that this strategy achieves better exacerbation control at a lower total drug load. A six-month trial compared budesonide-formoterol used for both purposes against fixed-dose salmeterol-fluticasone and fixed-dose budesonide-formoterol. The maintenance-and-reliever group had the lowest exacerbation rate, with about 12 events per 100 patients over six months, versus 19 in the salmeterol-fluticasone group, a roughly 39% reduction. And it managed this while patients used less steroid overall.¹⁶

Use in COPD

Budesonide formoterol is also used in COPD, though its role there is more selective. In a large trial, budesonide-formoterol prolonged the time to a first exacerbation compared with either component alone and reduced exacerbation risk by roughly 23–30% versus budesonide or formoterol given separately.¹⁷ A year-long trial showed that the higher-dose combination (320/9 micrograms) reduced COPD exacerbations by about 35% compared with formoterol alone and delayed the mean time to first exacerbation by roughly four weeks.¹⁸

Not every COPD patient benefits equally from the inhaled steroid component, though. Post-hoc analyses of large trials have found that the exacerbation-reducing effect of adding budesonide to formoterol becomes significant in patients whose blood eosinophil counts sit at or above about 100 cells per microliter.¹⁹ At higher eosinophil levels, the benefit grows proportionally.²⁰ Patients with very low eosinophil counts may see little added benefit from the steroid and could be managed with bronchodilators alone. Some researchers have also found that patients with higher eosinophils (above roughly 260 per microliter) are more than three times as likely to have a meaningful lung-function improvement after starting an inhaled steroid–long-acting bronchodilator combination.²¹ A simple blood test, in other words, can help clinicians predict who is most likely to benefit.

How It Compares with Fluticasone-Salmeterol

The most common alternative combination inhaler pairs fluticasone with salmeterol (sold as Advair or Seretide). The two combinations perform similarly in many respects, but real-world data and meta-analyses suggest some differences. In a year-long matched cohort of asthma patients, the budesonide-formoterol group had slightly fewer exacerbations per person-year and fewer asthma-related emergency department visits, though hospitalization rates were comparable.²²

In COPD, a recent meta-analysis found that budesonide-formoterol was associated with fewer hospitalizations and lower pneumonia rates compared with fluticasone-salmeterol.²³ A real-world matched-cohort study also found the budesonide-formoterol group had 25% fewer emergency department visits and 39% fewer COPD-related hospitalizations.²⁴ Much of this gap relates to pneumonia risk, discussed below.

Pneumonia Risk and Why the Steroid Choice Matters

A well-known concern with inhaled corticosteroids in COPD is an increased risk of pneumonia, but the risk is not equal across all steroids. Budesonide-formoterol has consistently shown a lower pneumonia signal than fluticasone-salmeterol. A large observational study of COPD patients found that budesonide-formoterol users had a 17% lower risk of severe pneumonia compared with fluticasone-salmeterol users, even after adjusting for the average daily steroid dose.²⁵ An earlier systematic review and indirect comparison found the odds of a pneumonia adverse event were about half as high with budesonide-formoterol compared with fluticasone-salmeterol.²⁶

When compared against placebo or formoterol alone (rather than fluticasone-salmeterol), the picture looks more reassuring. A meta-analysis of COPD trials found no significantly increased pneumonia risk with budesonide-formoterol compared with placebo, formoterol, or budesonide alone.²⁷ The difference between budesonide and fluticasone in this regard likely comes down to pharmacokinetic differences between the two steroids. Fluticasone is more lipophilic and tends to linger in lung tissue longer, which may suppress local immune defenses to a greater degree.

Common Side Effects

The most frequent side effects are local, related to the inhaled steroid component. Oral thrush (candidiasis) and voice hoarseness (dysphonia) are the standout issues. The same meta-analysis of COPD trials found that budesonide-formoterol users had roughly three times the rate of oral candidiasis and nearly three times the rate of dysphonia compared with placebo.²⁸ In clinical practice among asthma patients using inhaled steroids, the numbers are striking: roughly 80% report at least one local side effect in the mouth or throat, with dry throat and a sensation of thirst being the most common daily complaints. Rinsing your mouth after each use helps prevent candidiasis but does not protect the larynx, which is why voice symptoms and throat clearing persist even in patients with good oral hygiene habits after inhalation.²⁹

Systemic side effects from inhaled steroids are generally mild at standard doses. Adrenal suppression, the major concern with oral steroids, is unlikely at recommended inhaled doses. One large long-term study found no effects on adrenal function over three years of inhaled corticosteroid use. The threshold to watch is roughly 800 micrograms per day of budesonide equivalent: below this, the risk to bone mineral density and fracture is minimal, while higher doses may accelerate bone loss.³⁰

On the formoterol side, the main systemic effects are those shared by beta-2 agonists: a transient rise in heart rate, a dip in blood potassium, and a slight increase in blood glucose. These effects are dose-dependent. At standard inhaled doses (typically 4.5 to 9 micrograms per actuation), they are rarely clinically significant in most people. At higher doses, heart-rate effects become more pronounced, and patients with pre-existing cardiac arrhythmias warrant closer monitoring.³¹ The cardiovascular effects of formoterol appear faster in onset than those of salmeterol, consistent with formoterol’s overall faster pharmacokinetic profile.³²

Device Matters More Than You Might Think

Budesonide formoterol comes in two main inhaler types: a dry powder inhaler (DPI), commonly the Turbuhaler, and a pressurized metered-dose inhaler (pMDI). The devices are not interchangeable in terms of drug delivery. A landmark study showed that the Turbuhaler deposits roughly twice as much budesonide in the lungs as a standard pMDI, with less variability between puffs.³³ Despite this difference, clinical trials comparing the two devices head to head have found little meaningful difference in key outcomes like nighttime awakenings, total asthma symptom scores, or reliever medication use.³⁴ The implication is that pMDI formulations are dose-adjusted to compensate, but you should not assume one device can be swapped for the other at the same labeled dose without your prescriber’s input.

For patients who struggle with the coordination required to use a pMDI (press and breathe in simultaneously), a DPI may be easier because it is breath-activated. Conversely, patients with very weak inspiratory flow, common in severe COPD, may not generate enough airflow to empty a DPI properly and may do better with a pMDI plus spacer.

Cost-Effectiveness and the Adherence Advantage

One underappreciated benefit of the as-needed approach is that it sidesteps the biggest practical problem in asthma care: people not taking their daily controller. Adherence to daily inhaled steroids in the real world is notoriously poor, often below 50%. An as-needed-only regimen requires no daily habit, just reaching for the inhaler when symptoms appear. A Canadian cost-effectiveness analysis projected that as-needed budesonide-formoterol was the dominant option for mild asthma over a 50-year horizon, saving roughly $9,900 per patient while delivering a small gain in quality-adjusted life years compared with daily low-dose steroid maintenance plus an as-needed short-acting bronchodilator.³⁵

A New Zealand analysis based on trial data found that as-needed budesonide-formoterol was cost-saving from health-system, patient, and societal perspectives compared with daily budesonide plus as-needed salbutamol. Even compared with as-needed salbutamol alone, the combination was cost-effective from a health-system standpoint and cost-saving when productivity losses from asthma episodes were factored in.³⁶ Similar conclusions have been reached in other settings, including a Chinese analysis that found the maintenance-and-reliever strategy cost-effective against fixed-dose fluticasone-salmeterol plus a rescue inhaler.³⁷

Genetics and Response Variability

You might wonder whether genetic differences explain why some people respond well to budesonide formoterol and others do not. There has been particular interest in variants of the ADRB2 gene, which codes for the beta-2 receptor that formoterol binds to. The most studied variant involves a swap at position 16 of the protein (Gly16Arg). In two large COPD pharmacogenetic studies totaling nearly 2,900 patients, this variant did not significantly alter lung-function response to budesonide-formoterol, nor did it affect exacerbation rates or adverse events across different genotype groups.³⁸ So clinicians generally do not need to test for this variant before prescribing.

That said, a smaller study found that patients who carry specific combined variants in both the ADRB2 gene and the ADCY9 gene (which helps relay the bronchodilator’s signal inside the cell) had a measurably better lung-function improvement after two to three months of combination therapy.³⁹ Pharmacogenomic testing for inhaler response is not routine yet, but the research suggests that multi-gene interactions may eventually help tailor treatment more precisely.

The Environmental Angle

An issue gaining attention in respiratory medicine is the carbon footprint of inhalers. Pressurized metered-dose inhalers use hydrofluoroalkane propellants, potent greenhouse gases. Dry powder inhalers do not. A post-hoc analysis of trial data found that as-needed budesonide-formoterol delivered by DPI had a roughly 96% lower carbon footprint per person per year compared with as-needed salbutamol delivered by pMDI, and about 94% lower than a regimen of daily budesonide DPI plus as-needed salbutamol pMDI.⁴⁰ The large gap comes from two factors: the DPI avoids propellant gases entirely, and the as-needed strategy uses fewer total inhalations. For patients and clinicians who weigh environmental impact alongside clinical effectiveness, this is a meaningful consideration.

Pregnancy and Young Children

Uncontrolled asthma during pregnancy carries serious risks for both the mother and the baby, so clinicians generally prefer to continue controller therapy. Among inhaled steroids, budesonide has the most safety data in pregnancy and is considered compatible with use during pregnancy by most guidelines. However, the evidence is not without nuance. An animal model study found that both formoterol and budesonide (individually and in combination) could induce developmental defects including cleft palate and heart abnormalities in chick embryos, supporting epidemiological signals that anti-asthma drugs warrant caution during prenatal development.⁴¹ Animal models do not always predict human outcomes, and the risk of uncontrolled asthma during pregnancy (low birth weight, preterm delivery, preeclampsia) is well established. In practice, most professional societies recommend maintaining inhaled steroid therapy throughout pregnancy, with budesonide as the preferred agent because of its extensive safety record in human observational data. Discuss any medication changes with your prescriber before or early in pregnancy, rather than stopping treatment on your own.

1
PubMed. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma ↩︎
2
PubMed. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator ↩︎
3
PubMed Central. Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease ↩︎
4
PubMed. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling ↩︎
5
Proceedings of the American Thoracic Society. Interactions between Corticosteroids and β2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease ↩︎
6
PubMed. Budesonide/formoterol effects on metalloproteolytic balance in TGFbeta-activated human lung fibroblasts ↩︎
7
European Respiratory Journal. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma ↩︎
8
PubMed Central. Update on Asthma Management Guidelines ↩︎
9
PubMed. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma ↩︎
10
PubMed. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma ↩︎
11
The Lancet. Budesonide–formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL) ↩︎
12
The Journal of Allergy and Clinical Immunology: In Practice. Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma ↩︎
13
PubMed. Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE) ↩︎
14
JAMA Network Open. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma ↩︎
15
The Lancet Respiratory Medicine. Effect of a self-management programme involving budesonide–formoterol rescue and maintenance therapy on clinical outcomes in patients with persistent asthma ↩︎
16
PubMed Central. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations ↩︎
17
European Respiratory Journal. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease ↩︎
18
Respiratory Medicine. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease ↩︎
19
PubMed. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease ↩︎
20
American Journal of Respiratory and Critical Care Medicine. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease ↩︎
21
PubMed Central. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients ↩︎
22
The Journal of Allergy and Clinical Immunology: In Practice. Comparative Effectiveness of Budesonide-Formoterol and Fluticasone-Salmeterol in Asthma ↩︎
23
PubMed. Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease ↩︎
24
PubMed. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease ↩︎
25
PubMed. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β(2)-Agonist Combinations in Patients With COPD ↩︎
26
PubMed. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials ↩︎
27
PubMed Central. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis ↩︎
28
PubMed Central. Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis ↩︎
29
Jornal Brasileiro de Pneumologia. Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma ↩︎
30
Exploration of Asthma & Allergy. Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma ↩︎
31
PubMed. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia ↩︎
32
PubMed Central. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects ↩︎
33
European Respiratory Journal. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI ↩︎
34
PubMed Central. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma ↩︎
35
PubMed Central. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada ↩︎
36
European Respiratory Journal. Cost-effectiveness of as-needed budesonide-formoterol in adults with mild asthma: the Novel START trial ↩︎
37
PubMed. Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective ↩︎
38
PubMed Central. ADRB2 polymorphisms and budesonide/formoterol responses in COPD ↩︎
39
PubMed. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy ↩︎
40
European Respiratory Journal. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis ↩︎
41
PubMed Central. Anti-asthma Drugs Formoterol and Budesonide (Symbicort) Induce Orofacial Clefts, Gastroschisis and Heart Septum Defects in an In Vivo Model ↩︎